AML Breakapart LPH027

The AML1 (CBFA2 or RUNX1) gene is the most frequent target of chromosomal rearrangements observed in human acute leukemia. The most common rearrangements are the TEL/AML and AML/ETO fusions which provide for a favourable outcome whilst the TEL/AML1 fusion is associated with late relapse.

The AML1 gene is also involved in many other rare translocations including the partner chromosomes - 1, 2, 3, 4, 6, 9, 16, 20 and X. AML1 has also been found amplified in childhood ALL and is associated with a poorer outcome.

The Cytocell AML1 breakapart product has been designed to show gross changes in the AML1 gene without prior knowledge of any involvement of partner chromosome(s) as a rearrangement will be clearly visible in non-dividing cells as well as those at metaphase.